Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity of Hepatitis A Vaccine in Inflammatory Bowel Disease (IBD) Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients suffering from inflammatory bowel disease: Crohn's disease/Ulcerative colitis~2. Age 18-40~3. Willing to provide informed consent~Exclusion Criteria:~1. Have history of vaccination to hepatitis A~2. Have other autoimmune disease~3. Have any malignancy~4. Have acute infectious disease~5. Unwilling to provide consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- IBD patients (Type: EXPERIMENTAL): Patients diagnosed with IBD~-\> receive Epaxal Berna (virosomal hepatitis A vaccine)

Based on this trial design, predict the completion outcome and termination type (if applicable).